FY2017 EPS Estimates for Gilead Sciences, Inc. Cut by Analyst (GILD)
Gilead Sciences, Inc. (NASDAQ:GILD) – Jefferies Group cut their FY2017 EPS estimates for shares of Gilead Sciences in a report released on Wednesday. Jefferies Group analyst M. Yee now anticipates that the biopharmaceutical company will post earnings per share of $8.21 for the year, down from their previous forecast of $8.34. Jefferies Group has a “Positive” rating on the stock. Jefferies Group also issued estimates for Gilead Sciences’ Q1 2018 earnings at $1.58 EPS, Q2 2018 earnings at $1.54 EPS, Q3 2018 earnings at $1.49 EPS, Q4 2018 earnings at $1.52 EPS and FY2018 earnings at $6.15 EPS.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.11 by $0.45. The company had revenue of $7.14 billion during the quarter, compared to analysts’ expectations of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The business’s quarterly revenue was down 8.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $3.08 earnings per share.
COPYRIGHT VIOLATION WARNING: This report was originally published by Watch List News and is the property of of Watch List News. If you are reading this report on another site, it was illegally copied and republished in violation of international copyright and trademark legislation. The correct version of this report can be read at https://www.watchlistnews.com/fy2017-eps-estimates-for-gilead-sciences-inc-cut-by-analyst-gild/1616457.html.
Other analysts also recently issued research reports about the stock. TheStreet raised shares of Gilead Sciences from a “c+” rating to a “b-” rating in a research report on Thursday, September 7th. Zacks Investment Research upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $79.00 price objective on the stock in a research note on Monday, July 17th. Vetr cut Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $75.40 price objective on the stock. in a research note on Wednesday, June 21st. Deutsche Bank AG began coverage on Gilead Sciences in a research note on Friday, June 23rd. They issued a “buy” rating and a $79.00 price objective on the stock. Finally, Redburn Partners began coverage on Gilead Sciences in a report on Wednesday, July 26th. They set a “buy” rating for the company. Twelve analysts have rated the stock with a hold rating and twenty-one have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $85.66.
Gilead Sciences (NASDAQ GILD) opened at 82.14 on Friday. The firm has a market cap of $107.27 billion, a PE ratio of 8.92 and a beta of 1.14. Gilead Sciences has a 12-month low of $63.76 and a 12-month high of $86.27. The stock has a 50 day moving average of $80.97 and a 200 day moving average of $71.66.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 28th. Stockholders of record on Friday, September 15th were paid a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 2.53%. The ex-dividend date of this dividend was Thursday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is currently 22.58%.
In other news, EVP Gregg H. Alton sold 40,000 shares of the firm’s stock in a transaction dated Friday, July 21st. The stock was sold at an average price of $74.00, for a total value of $2,960,000.00. Following the transaction, the executive vice president now owns 137,488 shares of the company’s stock, valued at $10,174,112. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $75.86, for a total value of $5,563,041.38. Following the completion of the transaction, the insider now directly owns 3,199,969 shares in the company, valued at approximately $242,749,648.34. The disclosure for this sale can be found here. Insiders sold 486,819 shares of company stock worth $39,298,919 in the last ninety days. Corporate insiders own 1.30% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of GILD. Waldron LP raised its stake in shares of Gilead Sciences by 20.4% in the first quarter. Waldron LP now owns 10,360 shares of the biopharmaceutical company’s stock worth $711,000 after buying an additional 1,752 shares during the period. Mycio Wealth Partners LLC raised its stake in shares of Gilead Sciences by 13.0% in the first quarter. Mycio Wealth Partners LLC now owns 10,146 shares of the biopharmaceutical company’s stock worth $689,000 after buying an additional 1,165 shares during the period. Cubic Asset Management LLC raised its stake in shares of Gilead Sciences by 1.9% in the first quarter. Cubic Asset Management LLC now owns 29,701 shares of the biopharmaceutical company’s stock worth $2,017,000 after buying an additional 560 shares during the period. Dubuque Bank & Trust Co. raised its stake in shares of Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 267 shares during the period. Finally, Adviser Investments LLC bought a new position in shares of Gilead Sciences in the first quarter worth about $4,218,000. 73.99% of the stock is currently owned by hedge funds and other institutional investors.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.